Dean A. Wacker - Concepedia

Author

Dean A. Wacker

Bristol-Myers Squibb (United States)ORCID

Also Known As

D. Wacker, Dean A Wacker, Dean A. Wacker, Dean Wacker, Wacker, D.A.

Publications

741

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)University of California, Irvine Bristol-Myers Squibb (Germany)Experimental Station

About

Dean A. Wacker is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	355
2	Natural Sciences	4	4	160
3	Engineering	3	3	101
4	Social Sciences	1	1	34
5	Allergy	1	1	46

Dean A. Wacker

Publications

703

Citations

H-Index

Page 1

	Year	Citations
Site-specific incorporation of nonnatural residues during in vitro protein biosynthesis with semi-synthetic aminoacyl-tRNAs Jenny Bain, Edward S. Diala, Charles Glabe, Biochemistry	1991	103
Discovery of CC Chemokine Receptor-3 (CCR3) Antagonists with Picomolar Potency George V. De Lucca, Ui Tae Kim, Brian J. Vargo, Journal of Medicinal Chemistry	2005	62
Site-specific incorporation of non-natural residues into peptides: Effect of residue structure on suppression and translation efficiencies Jenny Bain, Dean A. Wacker, Eric E. Kuo, Tetrahedron Residue StructureBiochemistryProtein AssemblyProtein FoldingNatural Sciences	1991	59
Efficient solid-phase synthesis of 2,3-substituted indoles Dean A. Wacker, Padmaja Kasireddy Tetrahedron Letters Experimental SynthesisEngineeringOrganic ChemistryCatalysisChemistry	2002	53
CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure–activity relationships Dean A. Wacker, Joseph B. Santella, Daniel S. Gardner, Bioorganic & Medicinal Chemistry Letters AsthmaCcr3 AntagonistsPotential New TherapyAnti-inflammatoryAllergy	2002	46
Discovery of 5-Chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1<i>H</i>)-one (BMS-903452), an Antidiabetic Clinical Candidate Targeting GPR119 Dean A. Wacker, Ying Wang, Matthias Broekema, Journal of Medicinal Chemistry Pharmaceutical ScienceG-protein-coupled Receptor 119PharmacotherapyPharmaceutical ChemistryInsulin Signaling	2014	45
Structure–activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors Jeffrey Varnes, Dean A. Wacker, Donald Pinto, Bioorganic & Medicinal Chemistry Letters Structure–activity RelationshipBiochemistryMedicineMechanism Of ActionPharmacotherapy	2007	36
Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases. Dean A. Wacker, Keith J. Miller PubMed Serotonin Receptor FamilyPsychopharmacologyPharmacotherapyClinical ProgressionSocial Sciences	2008	34
Discovery of ( <i>R</i> )-9-Ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1- <i>a</i> ]isoindol- 6(2 <i>H</i> )-one, a Selective, Orally Active Agonist of the 5-HT <sub>2C</sub> Receptor Dean A. Wacker, Jeffrey Varnes, Sarah E. Malmstrom, Journal of Medicinal Chemistry	2007	33
From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: The discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis Joseph B. Santella, Daniel S. Gardner, Wenqing Yao, Bioorganic & Medicinal Chemistry Letters Combinatorial ChemistryMedicinal ChemistryAcyclic ScaffoldsMedicineNatural Sciences	2007	30

Page 1